# A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

> **NCT03033069** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 336 (actual)

## Conditions studied

- Stress Disorders, Post-Traumatic

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Sertraline
- **DRUG:** Brexpiprazole Matching Placebo
- **DRUG:** Sertraline Matching Placebo

## Key facts

- **NCT ID:** NCT03033069
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-26
- **Primary completion:** 2018-11-12
- **Final completion:** 2018-11-12
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2021-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033069, "A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03033069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*